CZ255197A3 - Použití 1-{4-[4-aryl (nebo heteroaryl)-1-piperazinyl]butyl}-1H-azolových derivátů pro přípravu léků pro použití při léčení obsedantních neuróz, syndromu spánkové apnoe, sexuálních disfunkcí, zvracení a kinetózy savců, včetně člověka - Google Patents
Použití 1-{4-[4-aryl (nebo heteroaryl)-1-piperazinyl]butyl}-1H-azolových derivátů pro přípravu léků pro použití při léčení obsedantních neuróz, syndromu spánkové apnoe, sexuálních disfunkcí, zvracení a kinetózy savců, včetně člověka Download PDFInfo
- Publication number
- CZ255197A3 CZ255197A3 CZ972551A CZ255197A CZ255197A3 CZ 255197 A3 CZ255197 A3 CZ 255197A3 CZ 972551 A CZ972551 A CZ 972551A CZ 255197 A CZ255197 A CZ 255197A CZ 255197 A3 CZ255197 A3 CZ 255197A3
- Authority
- CZ
- Czechia
- Prior art keywords
- butyl
- piperazinyl
- pyrimidinyl
- pyrazole
- imidazole
- Prior art date
Links
- 201000001880 Sexual dysfunction Diseases 0.000 title claims abstract description 14
- 231100000872 sexual dysfunction Toxicity 0.000 title claims abstract description 14
- 239000003814 drug Substances 0.000 title claims abstract description 9
- 206010047700 Vomiting Diseases 0.000 title claims description 16
- 230000008673 vomiting Effects 0.000 title claims description 14
- 241000124008 Mammalia Species 0.000 title claims description 4
- 208000008784 apnea Diseases 0.000 title description 4
- 125000001072 heteroaryl group Chemical group 0.000 title description 3
- 208000011580 syndromic disease Diseases 0.000 title 1
- 230000002123 temporal effect Effects 0.000 title 1
- 201000002859 sleep apnea Diseases 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 6
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 43
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 39
- -1 nitro, hydroxyl Chemical group 0.000 claims description 37
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Substances C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 13
- 125000003118 aryl group Chemical group 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 9
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 8
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- FMPJPCHSXGNEMD-UHFFFAOYSA-N 1-butylpyrazole Chemical compound CCCCN1C=CC=N1 FMPJPCHSXGNEMD-UHFFFAOYSA-N 0.000 claims description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 6
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 6
- 125000003277 amino group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 125000003107 substituted aryl group Chemical group 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 4
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 3
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 3
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 claims description 3
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 claims description 2
- 125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 claims description 2
- BGMONSPMFSWTDE-UHFFFAOYSA-N 1-[4-(4,5-dichloro-2-methylimidazol-1-yl)butyl]-4-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1CCN(CCCCN2C(=C(Cl)N=C2C)Cl)CC1 BGMONSPMFSWTDE-UHFFFAOYSA-N 0.000 claims 1
- SHPPDRZENGVOOR-UHFFFAOYSA-N 1-butylbenzimidazole Chemical compound C1=CC=C2N(CCCC)C=NC2=C1 SHPPDRZENGVOOR-UHFFFAOYSA-N 0.000 claims 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- QBRFAFGCHZMCPZ-UHFFFAOYSA-N 3-butyl-1,2-dihydroimidazole Chemical compound CCCCN1CNC=C1 QBRFAFGCHZMCPZ-UHFFFAOYSA-N 0.000 claims 1
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 claims 1
- MEAWMKXNZDOKST-UHFFFAOYSA-N 5-bromo-2-[4-(4-pyrazol-1-ylbutyl)piperazin-1-yl]pyrimidine Chemical compound N1=CC(Br)=CN=C1N1CCN(CCCCN2N=CC=C2)CC1 MEAWMKXNZDOKST-UHFFFAOYSA-N 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000001174 sulfone group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 206010025482 malaise Diseases 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 description 19
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 18
- AHCPKWJUALHOPH-UHFFFAOYSA-N lesopitron Chemical compound C1=C(Cl)C=NN1CCCCN1CCN(C=2N=CC=CN=2)CC1 AHCPKWJUALHOPH-UHFFFAOYSA-N 0.000 description 11
- 229950001590 lesopitron Drugs 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- MCMFEZDRQOJKMN-UHFFFAOYSA-N 1-butylimidazole Chemical compound CCCCN1C=CN=C1 MCMFEZDRQOJKMN-UHFFFAOYSA-N 0.000 description 6
- 230000029058 respiratory gaseous exchange Effects 0.000 description 6
- 230000009329 sexual behaviour Effects 0.000 description 6
- 230000007958 sleep Effects 0.000 description 6
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 5
- 229960002495 buspirone Drugs 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 102100022738 5-hydroxytryptamine receptor 1A Human genes 0.000 description 4
- 101710138638 5-hydroxytryptamine receptor 1A Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000000556 agonist Substances 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- TZJUVVIWVWFLCD-UHFFFAOYSA-N 1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 description 2
- 125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 2
- 208000027534 Emotional disease Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000282339 Mustela Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 2
- 229960004316 cisplatin Drugs 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 2
- 229960000647 gepirone Drugs 0.000 description 2
- 229950003599 ipsapirone Drugs 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 230000000414 obstructive effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 230000004620 sleep latency Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- VHFVKMTVMIZMIK-UHFFFAOYSA-N 1-(3-chlorophenyl)piperazine Chemical compound ClC1=CC=CC(N2CCNCC2)=C1 VHFVKMTVMIZMIK-UHFFFAOYSA-N 0.000 description 1
- WXDOCJUEBVNOAA-UHFFFAOYSA-N 2,3-dihydroxypropyl docosanoate;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO WXDOCJUEBVNOAA-UHFFFAOYSA-N 0.000 description 1
- XKXOJCMGWOFARI-UHFFFAOYSA-N 2,3-diphenyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]indole Chemical compound C1CN(C=2N=CC=CN=2)CCN1CCCCN(C1=CC=CC=C11)C(C=2C=CC=CC=2)=C1C1=CC=CC=C1 XKXOJCMGWOFARI-UHFFFAOYSA-N 0.000 description 1
- PRBGKQGYGPXWLE-UHFFFAOYSA-N 2-[4-(4-imidazol-1-ylbutyl)piperazin-1-yl]pyrimidine Chemical compound C1CN(C=2N=CC=CN=2)CCN1CCCCN1C=CN=C1 PRBGKQGYGPXWLE-UHFFFAOYSA-N 0.000 description 1
- LJAUERDRVNMYTC-UHFFFAOYSA-N 2-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]benzotriazole Chemical compound N1=C2C=CC=CC2=NN1CCCCN(CC1)CCN1C1=NC=CC=N1 LJAUERDRVNMYTC-UHFFFAOYSA-N 0.000 description 1
- AFSGIFILGYEOFI-UHFFFAOYSA-N 2-[4-[4-(2-phenylimidazol-1-yl)butyl]piperazin-1-yl]pyrimidine Chemical compound C1CN(C=2N=CC=CN=2)CCN1CCCCN1C=CN=C1C1=CC=CC=C1 AFSGIFILGYEOFI-UHFFFAOYSA-N 0.000 description 1
- LKFXALABNOXKPR-UHFFFAOYSA-N 2-[4-[4-(3,5-diphenylpyrazol-1-yl)butyl]piperazin-1-yl]pyrimidine Chemical compound C1CN(C=2N=CC=CN=2)CCN1CCCCN1N=C(C=2C=CC=CC=2)C=C1C1=CC=CC=C1 LKFXALABNOXKPR-UHFFFAOYSA-N 0.000 description 1
- CYYKVJCTRKJAFC-UHFFFAOYSA-N 2-[4-[4-(4-chloropyrazol-1-yl)butyl]piperazin-1-yl]benzonitrile Chemical compound C1=C(Cl)C=NN1CCCCN1CCN(C=2C(=CC=CC=2)C#N)CC1 CYYKVJCTRKJAFC-UHFFFAOYSA-N 0.000 description 1
- AFSMOCWESFBRCB-UHFFFAOYSA-N 2-[4-[4-(4-phenylimidazol-1-yl)butyl]piperazin-1-yl]pyrimidine Chemical compound C1CN(C=2N=CC=CN=2)CCN1CCCCN(C=1)C=NC=1C1=CC=CC=C1 AFSMOCWESFBRCB-UHFFFAOYSA-N 0.000 description 1
- SLLDUURXGMDOCY-UHFFFAOYSA-N 2-butyl-1h-imidazole Chemical compound CCCCC1=NC=CN1 SLLDUURXGMDOCY-UHFFFAOYSA-N 0.000 description 1
- CJAWPFJGFFNXQI-UHFFFAOYSA-N 2-chloro-6-(1-piperazinyl)pyrazine Chemical compound ClC1=CN=CC(N2CCNCC2)=N1 CJAWPFJGFFNXQI-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- 229940000681 5-hydroxytryptophan Drugs 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- ASXGJMSKWNBENU-UHFFFAOYSA-N 8-OH-DPAT Chemical compound C1=CC(O)=C2CC(N(CCC)CCC)CCC2=C1 ASXGJMSKWNBENU-UHFFFAOYSA-N 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 206010057671 Female sexual dysfunction Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101000847160 Homo sapiens Xylosyltransferase 2 Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010057672 Male sexual dysfunction Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000282341 Mustela putorius furo Species 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- YZOCCMZHFRVWAC-UHFFFAOYSA-N N1=C(N=CC=C1)CCCC(N1CCNCC1)C=1C=NNC1 Chemical compound N1=C(N=CC=C1)CCCC(N1CCNCC1)C=1C=NNC1 YZOCCMZHFRVWAC-UHFFFAOYSA-N 0.000 description 1
- 101000986989 Naja kaouthia Acidic phospholipase A2 CM-II Proteins 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102100032728 Xylosyltransferase 2 Human genes 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000036626 alertness Effects 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 101150047356 dec-1 gene Proteins 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036044 hypoxaemia Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- NTDNRPNORCEPQE-UHFFFAOYSA-N n-butan-2-yl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]pyrazol-4-amine Chemical compound C1=C(NC(C)CC)C=NN1CCCCN1CCN(C=2N=CC=CN=2)CC1 NTDNRPNORCEPQE-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 208000001797 obstructive sleep apnea Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001107 psychogenic effect Effects 0.000 description 1
- 230000001003 psychopharmacologic effect Effects 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000036387 respiratory rate Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 230000002295 serotoninergic effect Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000004622 sleep time Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9514690A FR2742052B1 (fr) | 1995-12-12 | 1995-12-12 | Utilisation des derives 1-(4-(4-aryl (ou heteroaryl)-1-piper azinyl)-buty)-1h-azole pour le traitement de la depression, des troubles obsessifs compulsifs, l'apnee du sommeil, les dysfonctions sexuelles, l'emese et le mal des transports |
Publications (1)
Publication Number | Publication Date |
---|---|
CZ255197A3 true CZ255197A3 (cs) | 1998-01-14 |
Family
ID=9485400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CZ972551A CZ255197A3 (cs) | 1995-12-12 | 1996-12-11 | Použití 1-{4-[4-aryl (nebo heteroaryl)-1-piperazinyl]butyl}-1H-azolových derivátů pro přípravu léků pro použití při léčení obsedantních neuróz, syndromu spánkové apnoe, sexuálních disfunkcí, zvracení a kinetózy savců, včetně člověka |
Country Status (16)
Country | Link |
---|---|
EP (1) | EP0808166A1 (de) |
JP (1) | JPH11501051A (de) |
CN (1) | CN1177297A (de) |
AR (1) | AR004378A1 (de) |
AU (1) | AU716665B2 (de) |
CA (1) | CA2211161A1 (de) |
CZ (1) | CZ255197A3 (de) |
ES (1) | ES2134709B1 (de) |
FR (1) | FR2742052B1 (de) |
HU (1) | HUP9800198A2 (de) |
IL (1) | IL121461A0 (de) |
NO (1) | NO973589L (de) |
PL (1) | PL321779A1 (de) |
TR (1) | TR199700794T1 (de) |
WO (1) | WO1997021439A1 (de) |
ZA (1) | ZA9610457B (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2763950B1 (fr) | 1997-06-02 | 2002-09-20 | Esteve Labor Dr | 2- {4- [4-(4,5-dichloro-2-methylimidazol-1-yl)butyl] -1- piperazinyl }-5-fluoropyrimidine, sa preparation et son utilisation therapeutique |
TW526202B (en) * | 1998-11-27 | 2003-04-01 | Shionogi & Amp Co | Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity |
US6046331A (en) * | 1998-12-17 | 2000-04-04 | Synaptic Pharmaceutical Corporation | Imidazolones and their use in treating benign prostatic hyperplasia and other disorders |
CA2419552C (en) | 2000-08-14 | 2010-10-12 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted pyrazoles |
DK1309592T3 (da) | 2000-08-14 | 2006-08-21 | Ortho Mcneil Pharm Inc | Substituerede pyrazoler |
US7332494B2 (en) | 2000-08-14 | 2008-02-19 | Janssen Pharmaceutica, N.V. | Method for treating allergies using substituted pyrazoles |
MXPA03001421A (es) | 2000-08-14 | 2004-01-26 | Johnson & Johnson | Pirazoles sustituidos. |
CN1642973A (zh) | 2000-09-06 | 2005-07-20 | 奥索-麦克尼尔药品公司 | 治疗变态反应的方法 |
US7795266B2 (en) | 2003-09-25 | 2010-09-14 | Helton David R | Tetrahydroindolone derivatives for treament of neurological conditions |
WO2005094827A1 (en) * | 2004-03-30 | 2005-10-13 | Kestrel Pharmaceuticals Inc. | Methods for treating sexual dysfunction |
PT1877390E (pt) * | 2005-04-26 | 2010-05-31 | Hypnion Inc | Compostos benzisoxazole-piridina e métodos para a sua utilização |
WO2006116615A1 (en) | 2005-04-26 | 2006-11-02 | Hypnion, Inc. | Benzisoxazole piperazine compounds and methods of use thereof |
GB2435827A (en) * | 2006-03-09 | 2007-09-12 | Del Dr Esteve S A Spain Lab | Use of substituted piperazine compounds for the treatment of food related disorders |
CN115304590B (zh) * | 2022-09-19 | 2024-05-28 | 皮摩尔新药(辽宁)有限公司 | 2h-苯并三氮唑衍生物及其制备方法及含有它们的药物组合物 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2672052B1 (fr) * | 1991-01-28 | 1995-05-24 | Esteve Labor Dr | Derives d'aryl (ou heteroaryl)-piperazinyl-alkyl-azoles, leur preparation et leur application en tant que medicaments. |
FR2723091B1 (fr) * | 1994-07-29 | 1996-11-08 | Esteve Labor Dr | Tetrahydropyridine-(6,4-hydroxypiperidine) alkylazoles |
-
1995
- 1995-12-12 FR FR9514690A patent/FR2742052B1/fr not_active Expired - Fee Related
-
1996
- 1996-12-11 WO PCT/EP1996/005736 patent/WO1997021439A1/fr not_active Application Discontinuation
- 1996-12-11 PL PL96321779A patent/PL321779A1/xx unknown
- 1996-12-11 HU HU9800198A patent/HUP9800198A2/hu unknown
- 1996-12-11 AU AU13764/97A patent/AU716665B2/en not_active Ceased
- 1996-12-11 JP JP9521756A patent/JPH11501051A/ja active Pending
- 1996-12-11 EP EP96944029A patent/EP0808166A1/de not_active Withdrawn
- 1996-12-11 CN CN96192286A patent/CN1177297A/zh active Pending
- 1996-12-11 CA CA002211161A patent/CA2211161A1/fr not_active Abandoned
- 1996-12-11 CZ CZ972551A patent/CZ255197A3/cs unknown
- 1996-12-11 TR TR97/00794T patent/TR199700794T1/xx unknown
- 1996-12-11 IL IL12146196A patent/IL121461A0/xx unknown
- 1996-12-12 AR ARP960105644A patent/AR004378A1/es unknown
- 1996-12-12 ZA ZA9610457A patent/ZA9610457B/xx unknown
- 1996-12-12 ES ES009602700A patent/ES2134709B1/es not_active Expired - Lifetime
-
1997
- 1997-08-04 NO NO973589A patent/NO973589L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
FR2742052B1 (fr) | 1998-04-10 |
TR199700794T1 (xx) | 1997-11-21 |
IL121461A0 (en) | 1998-02-08 |
PL321779A1 (en) | 1997-12-22 |
AR004378A1 (es) | 1998-11-04 |
AU1376497A (en) | 1997-07-03 |
CA2211161A1 (fr) | 1997-06-19 |
ES2134709B1 (es) | 2000-05-16 |
NO973589L (no) | 1997-10-08 |
JPH11501051A (ja) | 1999-01-26 |
CN1177297A (zh) | 1998-03-25 |
WO1997021439A1 (fr) | 1997-06-19 |
EP0808166A1 (de) | 1997-11-26 |
AU716665B2 (en) | 2000-03-02 |
NO973589D0 (no) | 1997-08-04 |
MX9706133A (es) | 1997-11-29 |
ZA9610457B (en) | 1997-06-24 |
HUP9800198A2 (hu) | 1999-09-28 |
ES2134709A1 (es) | 1999-10-01 |
FR2742052A1 (fr) | 1997-06-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20230116233A1 (en) | Compounds And Compositions As Protein Kinase Inhibitors | |
CZ255197A3 (cs) | Použití 1-{4-[4-aryl (nebo heteroaryl)-1-piperazinyl]butyl}-1H-azolových derivátů pro přípravu léků pro použití při léčení obsedantních neuróz, syndromu spánkové apnoe, sexuálních disfunkcí, zvracení a kinetózy savců, včetně člověka | |
AU2014272776C1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of disease | |
AU613662B2 (en) | Lactam derivatives | |
US11542278B1 (en) | Heteroaromatic macrocyclic ether chemotherapeutic agents | |
CA3050188C (en) | Imidazopyrazine compounds, preparation methods and uses thereof | |
EP4146205A1 (de) | Heteroaromatische makrozyklische ether als chemotherapeutische mittel | |
BR0110302A (pt) | Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase | |
US20170001967A1 (en) | Piperazine derivatives having multimodal activity against pain | |
JP2000507595A (ja) | ファルネシルプロテイントランスフェラーゼの阻害剤 | |
HU215125B (hu) | Eljárás 3-[aril-(tio)karbonil]-1-amino-alkil-1H-indol-származékokat tartalmazó, glaukóma-elleni gyógyszerkészítmények előállítására | |
JPH07242626A (ja) | 胃酸分泌抑制剤及び抗潰瘍剤 | |
JP2006516604A (ja) | 5ht7アンタゴニストおよび逆アゴニスト | |
US20200261463A1 (en) | Treatment of cancer using aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide compounds | |
CN115916196A (zh) | 杂芳族大环醚化学治疗剂 | |
CZ292015B6 (cs) | Použití derivátů tetrahydropyridin (nebo 4-hydropiperidin) - butylazolů při přípravě léčiva pro léčbu bolesti | |
MXPA97006133A (es) | Uso de los derivados de 1-{4-[4-aril(o heteroaril)-1-piperazinil]-butil}-1h-azol para la preparacion de un medicamento destinado al tratamiento de lostrastornos obsesivo-compulsivos, de la apnea delsueño, de las disfunciones sexuales, de la emesis | |
MXPA97009396A (es) | Derivados de fenoxipiperazina para el tratamientode transtornos del sistema dopamina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PD00 | Pending as of 2000-06-30 in czech republic |